In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
We evaluated the potency of garenoxacin in selecting resistant Streptococcus pneumoniae mutants by determining its mutant prevention concentration, using strains with and without topoisomerase gene mutations, and compared its potency to that of other quinolones. Garenoxacin had a significantly greater potency against pneumococci, including strains containing topoisomerase mutations. Genetic analysis of the S. pneumoniae mutants created by garenoxacin revealed that the gyrA gene was a primary target of garenoxacin.
Yamamoto
Kazuko
K
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Japan.
Yanagihara
Katsunori
K
Sugahara
Kazuyuki
K
Imamura
Yoshifumi
Y
Seki
Masafumi
M
Izumikawa
Koichi
K
Kakeya
Hiroshi
H
Yamamoto
Yoshihiro
Y
Hirakata
Yoichi
Y
Kamihira
Shimeru
S
Kohno
Shigeru
S
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D027081:DNA Gyrase / Q000235:genetics / Q000502:physiology; D026942:DNA Topoisomerases / Q000235:genetics / Q000502:physiology; D024881:Drug Resistance, Bacterial / Q000187:drug effects / Q000235:genetics; D024841:Fluoroquinolones / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000235:genetics*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D026942:DNA Topoisomerases; D027081:DNA Gyrase; C419689:garenoxacin